Angiotensin II suppresses autophagy and disrupts ultrastructural morphology and function of mitochondria in mouse skeletal muscle. Angiotensin II (ANG II)-induced skeletal muscle wasting is characterized by activation of the ubiquitin-proteasome system. However, the potential involvement of proteolytic system macroautophagy/autophagy in this wasting process remains elusive. Autophagy is precisely regulated to maintain cell survival and homeostasis; thus its dysregulation (i.e., overactivation or persistent suppression) could lead to detrimental outcomes in skeletal muscle. Here we show that infusion of ANG II for 7 days in male FVB mice suppressed autophagy in skeletal muscle. ANG II blunted microtubule-associated protein 1 light chain 3B (LC3B)-I-to-LC3B-II conversion (an autophagosome marker), increased p62/SQSTM1 (an autophagy cargo receptor) protein expression, and decreased the number of autophagic vacuoles. ANG II inhibited UNC-51-like kinase 1 via inhibition of 5=-AMP-activated kinase and activation of mechanistic target of rapamycin complex 1, leading to reduced phosphorylation of beclin-1 Ser14 and Autophagy-related protein 14 Ser29 , suggesting that ANG II impairs autophagosome formation in skeletal muscle. In line with ANG II-mediated suppression of autophagy, ANG II promoted accumulation of abnormal/damaged mitochondria, characterized by swelling and disorganized cristae and matrix dissolution, with associated increase in PTEN-induced kinase 1 protein expression. ANG II also reduced mitochondrial respiration, indicative of mitochondrial dysfunction. Together, these results demonstrate that ANG II reduces autophagic activity and disrupts mitochondrial ultrastructure and function, likely contributing to skeletal muscle wasting. Therefore, strategies that activate autophagy in skeletal muscle have the potential to prevent or blunt ANG II-induced skeletal muscle wasting in chronic diseases.
INTRODUCTION
Systemic levels of angiotensin II (ANG II) are elevated in chronic diseases such as heart failure, chronic kidney disease, and cancer (13, 45, 67) . We and others have previously shown that ANG II contributes to skeletal muscle wasting (45, 53, 58, 67) , suggesting that persistently elevated ANG II levels worsen the prognosis of these patients. In fact, ANG II has been recently implicated as a master upstream regulator of cachexia in cancer patients (45) . Multiple studies have shown that ANG II induces skeletal muscle proteolysis via activation of the ubiquitin-proteasome system (UPS) (7, 15, 53, 65, 67) . The UPS and the macroautophagy system (hereafter referred to as autophagy) are the two major intracellular protein degradation pathways (5, 36, 54, 64) , but the potential involvement of autophagy in ANG II-mediated skeletal muscle wasting remains elusive.
In autophagy, a double-membrane autophagy-related organelle (autophagosome) is formed to engulf different intracellular components (i.e., nonselective autophagy) or a specific intracellular structure (i.e., selective autophagy), where upon fusion with lysosomes its contents undergo hydrolase-dependent degradation (5, 24, 38, 55) . Autophagy has been shown to induce skeletal muscle proteolysis during prolonged starvation, denervation, and cancer by excessive capture and accelerated degradation of autolysosomal contents (41, 54) . Therefore, we initially hypothesized that ANG II would promote autophagymediated skeletal muscle proteolysis. Instead, we found that ANG II impairs the autophagy-initiating signaling pathway in skeletal muscle, leading to decreased autophagosome formation. It is highly likely that the reduced skeletal muscle autophagic flux impairs clearance of unwanted/damaged organelles such as mitochondria. In fact, our data show that the Lysosomal Associated Membrane Protein 1 (LAMP1, 1:1,000; no. ab24170), and Cytochrome-c oxidase, complex IV mitochondrial loading control (1:1,000; no. ab16056) from Abcam (Cambridge, UK); Fission 1 (Fis1, 1:1,000; no. 10956-1-AP) from Proteintech (Rosemont, IL); phospho-beclin-1 Ser15 (Ser14 in mice, 1:500; no. 254515) from Abbiotec (San Diego, CA); and phospho-p70 S6K T389 (1:1,000; no. 9234), p70 S6K (1:1, 000; no. 2708); phospho-S6 Ser240/244 (1:1,000; no. 5364), S6 (1:1,000; no. 2217), phospho-ATG14 Ser29 (1:1,000; no. 96752), 5=-AMP-activated kinase (AMPK, 1:1,000; no. 2532), phospho-AMPK Thr172 (1:1,000; no. 2535), UNC-51-like kinase 1 (ULK1, 1:1,000; no. 8054), phospho-ULK1 Ser317 (1:1,000; no. 12755), p-ULK1 S555 (1:1,000; no. 5869), phospho-ULK1 Ser757 (1:1,000; no. 6888), Mitofusin-2 (1:1,000; no. 9482), Optic Atrophy 1 (OPA1, 1:1,000; no. 80471), Cytochrome c (1:1,000; no. 136F3), and ␣-Tubulin (1:1,000; no. 9099) from Cell Signaling Technology (Danvers, MA).
Quantitative RT-PCR. Total RNA from pulverized TA muscles was isolated as previously described (61, 65) . Expression of Macrotubule-Associated Protein 1 Light Chain 3␤ (Map1lc3b; no. PPM27261A-200) and p62/Sqstm1 (no. PPM28731F-200) was analyzed by quantitative RT-PCR and normalized to the expression of the housekeeping gene Hprt1 (no. PPM03559F-200) (12, 22) . The PCR primers were obtained from Qiagen (Germantown, MD).
Cathepsin B and L activity assays. Cathepsin B and L activity assays were performed as previously described with minor modifications (4) . Briefly, gastrocnemius muscle pulverized under liquid nitrogen (~15 mg) was homogenized in lysis buffer [in mM: 50 Tris·HCl (pH 7.5), 150 NaCl, 1 EDTA, 5 MgCl 2, and 0.5 DTT]. Cathepsin BϩL activity was measured by mixing 20 g of protein with 50 l of cathepsin B and L reaction buffer (in mM: 100 mM acetate (pH 5.5), 1 EDTA, and 2 DTT] and 1 mM cathepsin B and L substrate Z-Phe-Arg-AMC (MilliporeSigma; no. 03-32-1501). Fluorescence intensity (excitation 380 nm; emission 460 nm) was measured in a kinetics-based assay for 90 min at 37°C with a Cytation 5 Cell Imaging Multi-Mode Reader (Biotek, Winooski, VT). For cathepsin L activity measurement, the same set of samples was incubated for 15 min at RT with cathepsin B inhibitor (MilliporeSigma; no. 219385) before the addition of cathepsin BϩL substrate. Cathepsin B activity was calculated by subtracting the cathepsin L activity from the cathepsin BϩL activity.
Isolation of enriched mitochondrial fraction. Mitochondria were isolated as described previously (6, 21) , with minor modifications. Briefly, freshly isolated TA muscles were rinsed in ice-cold PBS, minced, and incubated in isolation buffer for mitochondria 1 [IBm1; in mM: 67 sucrose, 50 Tris·HCl (pH 7.4), 50 KCl, and 10 EDTA, with 0.2% BSA] plus trypsin-EDTA (0.25%) for 30 min on ice. Then muscles were centrifuged at 200g for 3 min at 4°C. Muscles were manually homogenized in ice-cold IBm1 with a Kimble Kontes Dounce tissue grinder (30 strokes; Fisher Scientific, Hampton, NH; no. K885300) and centrifuged at 700g for 10 min at 4°C. The supernatants were collected and further centrifuged at 8,000g for 10 min at 4°C. The pellet was washed, suspended in IBm2 (in mM: 220 mannitol, 70 sucrose, 5 EGTA, and 10 Tris·HCl pH 7.4), and centrifuged at 8,000g for 10 min at 4°C. The final pellet (enriched mitochondrial fraction) was suspended in 100 l of IBm2 and kept on ice until ready to use. Protein concentration was measured by the bicinchoninic method.
Mitochondria respiration assay (oxygen consumption rate). Mitochondrial oxygen consumption rate was assessed with XF e 96 Agilent Seahorse technology (Agilent, Santa Clara, CA). Enriched mitochondrial fractions were mixed in two different combinations of respiratory substrates and an inhibitor: pyruvate (10 mM) and malate (5 mM) for the complex I-mediated respiratory rates and succinate (10 mM) and rotenone (2 M) for the complex II-mediated respiration rates. In the presence of the substrate-inhibitor combinations, mitochondria (2 g and 1.5 g for complex I and complex II assay, respectively) were seeded in the XF e 96 Agilent Seahorse culture plate and centrifuged at 2,000g for 20 min at 4°C. The culture plate was warmed at 37°C for 10 min and placed in the XF e 96 Agilent Seahorse machine. Oxygen consumption rate was measured by sequential injections of 5 mM ADP, 2 M oligomycin, 4 M carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), and 4 M antimycin A. The experiment was performed in three replicates per mouse for each respiratory substrate-inhibitor combination for the PF and ANG II groups after 7 days of infusion.
Skeletal muscle ultrastructural morphology. Ultrastructural morphology of extensor digitorum longus (EDL) muscle was analyzed by transmission electronic microscopy (TEM). After each experimental period, EDL muscle was harvested, weighed, and incubated in fixation solution (2% paraformaldehyde, 2% glutaraldehyde in 100 mM sodium cacodylate buffer pH 7.35) for 30 min (RT). After fixation, EDL muscle was rinsed with 100 mM sodium cacodylate buffer (pH 7.35) containing 130 mM sucrose. Secondary fixation was performed with 1% osmium tetroxide (Ted Pella, Redding, CA) in cacodylate buffer with a Pelco Biowave (Ted Pella) operated at 100 W for 1 min. After incubation at 4°C for 1 h, samples were rinsed with cacodylate buffer and further with distilled water. En bloc staining was performed with 1% aqueous uranyl acetate, incubated at 4°C overnight, and rinsed with distilled water. With the Pelco Biowave, a graded dehydration series (ethanol to acetone, 100 W for 40 s per exchange) was performed. Dehydrated tissues were then infiltrated with Epon resin (250 W for 3 min) and polymerized at 60°C overnight. Eighty-fivenanometer sections were cut with an ultramicrotome (Ultracut UCT; Leica Microsystems) and a diamond knife (Diatome, Hatfield, PA). Images were acquired with a JEOL JEM 1400 transmission electron microscope (JEOL, Peabody, MA) at 80 kV on a Gatan Ultrascan 1000 CCD (Gatan, Pleasanton, CA). Analysis of mitochondrial area and identification of abnormal mitochondria were performed by two investigators, one of whom was blinded to the identity of samples. Mitochondrial area was quantified with Olympus cellSens Dimension Desktop 1.13 (Olympus, Tokyo, Japan). Abnormal mitochondria were defined by 1) total or partial disarrangements of the cristae, 2) presence of matrix dissolution, and 3) swollen shape, as characterized and described elsewhere (2, 14, 31) . The term "autophagic vacuoles" was adopted to designate the morphological characteristics of autophagosomes and autolysosomes as described elsewhere (17) . Au-tophagic vacuoles were identified and counted as previously reported (19, 63) . Total autophagosome and autolysosome numbers were normalized per viewing field.
Statistical analysis. All data are presented as means Ϯ SD, and a P value Ͻ0.05 is considered significant. Data were analyzed (GraphPad Prism, version 7) by Student's t-test (comparison between 2 experimental groups), one-way ANOVA followed by Tukey's multiplecomparison test (for comparison of 3 groups), and two-way ANOVA for nonrepeated measurements followed by Bonferroni's multiplecomparison test (for comparison of groups with 2 independent variables).
RESULTS

ANG II increases SBP and induces loss of skeletal muscle mass.
Consistent with our previous studies (7, 59, 61, 66) , ANG II infusion significantly increased SBP ( Fig. 1A ) and reduced food intake ( Fig. 1B ;~52% reduction in ANG II compared with Sham at 7 days). A marked loss in total body weight was also observed upon ANG II infusion compared with Sham and PF groups (Sham 28.9 Ϯ 2.5 g, PF 25.9 Ϯ 1.3 g vs. ANG II 23.7 Ϯ 2.8 g; P Ͻ 0.05, n ϭ 6/group at 7 days). Notably, ANG II infusion resulted in a significant loss in skeletal muscle weight after 7 days in both gastrocnemius ( Fig. 1D and data not shown for TA; 12 h, n ϭ 5; 1 day, n ϭ 6; 4 days, n ϭ 6; P ϭ not significant, PF vs. ANG II).
ANG II impairs autophagic flux in skeletal muscle. Compared with the Sham group, the conversion from the diffused cytoplasmic form (LC3B-I) to the lipidated form (LC3B-II), hereafter referred as to LC3B conversion, was significantly increased (Fig. 2, A and B ) and protein expression of p62 was decreased (Fig. 2 , A and C) in the PF group, likely because of A: ANG II (1.0 g·kg Ϫ1 ·min Ϫ1 ) infusion increased systolic blood pressure. n ϭ 6/group. **P Ͻ 0.005 for ANG II vs. Sham and pair fed (PF) groups from day 3 to day 6. B: ANG II decreased food intake throughout 7 days of experimental period. n ϭ 6/group. *P Ͻ 0.05, **P Ͻ 0.005 from day 1 to day 7;~52% reduction at 7 days. C: gastrocnemius muscle mass at 7 days of ANG II infusion. n ϭ 6/group. *P Ͻ 0.05 for Sham vs. PF and for PF vs. ANG II; ****P Ͻ 0.0001 for Sham vs. ANG II. D: gastrocnemius muscle mass measured in PF (Ϫ) and ANG II (ϩ) groups at 12 h and 1, 4, and 7 days of infusion. n ϭ 5/group and P ϭ not significant (NS) for 12 h; n ϭ 6/group and P ϭ NS for 1 day; n ϭ 6/group and P ϭ NS for 4 days; n ϭ 6/group and *P Ͻ 0.05 for 7 days]. Ten-to twelve-week old male FVB mice were used for all experiments. All data are means Ϯ SD. caloric restriction-mediated autophagy activation. Furthermore, ANG II infusion inhibited LC3B conversion to levels similar to that seen in the Sham group (Fig. 2, A and B) . However, a marked increase in p62 levels was observed after ANG II infusion compared with Sham and PF groups (Fig. 2 , A and C). Detailed time course analysis revealed dynamic changes in LC3B conversion and p62 level (12 h to 7 days of infusion; Fig. 2 , D-F). Although LC3B conversion was gradually increased in PF, ANG II blunted this increase. In contrast, p62 level remained constant in PF throughout the experimental period, whereas ANG II gradually increased p62 (Fig. 2 , D and F). It has been reported that analysis of static levels of LC3B-II-to-LC3B-I ratio may be misleading because LC3B conversion and subsequent degradation are dynamically regulated (29) . To further confirm the effect of ANG II on autophagic activity, animals were treated (for 2 days) with colchicine, an autophagic flux blocker (29, 37) , after 1 day or 7 days of ANG II infusion. Although a trend in increase in LC3B conversion in the ANG IIϩcolchicine group was observed compared with PFϩcolchicine at 1 day, it was not statistically significant ( . Of note, LC3B and p62 mRNA levels were not altered by ANG II (Fig. 2, N and O) , indicating that these changes in autophagy markers are regulated at the posttranscriptional level. To further demonstrate that ANG II impairs autophagy, we quantified the number of autophagic vacuoles (i.e., autophagosomes and autolysosomes) in EDL muscles by TEM. Since low numbers of autophagic vacuoles were observed by TEM (data not shown and Fig. 3C ), the animals were treated with colchicine to block autophagic flux. Under this condition, ANG II-infused mice showed a significant reduction in the number of autophagic vacuoles compared with PF mice in both subsarcolemmal and intramyofibrillar areas ( Fig. 3 ). These data are consistent with reduced LC3B conversion and increased p62 levels ( Fig. 2 ) and together indicate that ANG II induces mitochondria depolarization as early as 24 h of infusion but fails to induce autophagosome formation. Lysosome function is not altered in ANG II-infused mice. Having demonstrated that ANG II inhibits autophagosome formation (Figs. 2 and 3), we next determined whether ANG II regulates lysosomal content and/or function. LAMP1 and LAMP2 comprise~50% of total lysosome proteins (18) . The data show no significant difference in LAMP1 protein expression between ANG II and PF groups (Fig. 4, A and B suggesting that ANG II did not alter lysosomal content. Furthermore, no difference in lysosomal enzymatic activity (cathepsins BϩL) was detected between ANG II and PF groups (Fig.  4, C and D) . These data indicate that decreased autophagic flux after ANG II infusion is not associated with altered lysosomal content or activity.
Signaling pathways involved in autophagosome formation are disrupted in ANG II-infused mice. AMPK and mechanistic target of rapamycin complex 1 (mTORC1) regulate autophagy induction (30) . Our data show that although ANG II reduced phosphorylation of AMPK (Thr172) compared with PF at 4 days (Fig. 5, A and B) , it increased phosphorylation of mTORC1 downstream targets S6K1 (Thr389) at 4 and 7 days and S6 (Ser240/244) at 7 days ( Fig. 5, A, C, and D) . It has been previously reported that although AMPK induces ULK1 phosphorylation at Ser317 and Ser555, mTORC1 induces ULK1 phosphorylation at Ser757. Our data show that ANG II reduced p-ULK1 (Ser317) at 7 days (Fig. 5, E and F) , while p-ULK1 (Ser555) was not altered (Fig. 5 , E and G; at 4 days P ϭ 0.10). In contrast, p-ULK1 (Ser757) was increased at 4 days (Fig. 5, E and H) . After ULK1 activation, the VPS34 forms a complex (VPS34-VPS15-beclin-1-ATG14) to initiate autophagosome formation (i.e., the isolation membrane). Although VPS34 protein level was not altered by ANG II (Fig. 5, I and L) , an increase in p-beclin-1 (Ser14) was detected in the PF group, likely because of reduced food intake and mTORC1 inhibition, and ANG II blunted this increase (Fig. 5, I and J) . Furthermore, ANG II decreased p-ATG14 (Ser29) levels (Fig. 5, I and K) .
ANG II causes accumulation of abnormal mitochondria in skeletal muscle. Defective autophagy can be detrimental to skeletal muscle and may lead to accumulation of intracellular waste of damaged and dysfunctional organelles such as mitochondria (i.e., reduced mitophagy) (23, 48) . To determine whether ANG II-mediated impairment of autophagy induces morphological changes and/or dysfunction of mitochondria, we analyzed mitochondrial ultrastructure by TEM. We ob-served~3% of abnormal mitochondria (swollen shape and having disorganized cristae and matrix dissolution) in the PF group throughout the experimental period (Fig. 6, A and C) . ANG II did not alter the number of abnormal mitochondria at earlier time points of infusion ( Fig. 6A; 12 h, 1 days, and 4 days), but it increased significantly after 7 days of infusion (~10%, Fig. 3, A and B, and Fig. 6 , A-C). Furthermore, ANG II shifted the frequency distribution of mitochondrial size toward larger mitochondria ( Fig. 6D ) and increased average mitochondrial area (Fig. 6E) . Importantly, mitochondria from the ANG II group had decreased number of cristae ( Fig. 6F ) and length of each crista (Fig. 6G) .
Skeletal muscle from ANG II-infused mice display reduced aerobic respiratory capacity. To evaluate whether the increase in the number of abnormal mitochondria observed by TEM is associated with decreased function of this organelle, we analyzed mitochondrial respiration with the Seahorse XF e 96 analyzer. Although ANG II infusion did not affect basal respiratory rates (state II or pseudo-state IV), maximal ADP-stimulated respiration (state III ADP ) and FCCP-stimulated maximal respiration were decreased in the ANG II group in the complex I assay (Fig. 7A) . With regard to complex II-mediated mitochondrial respiration, we found a significant decrease in basal respiratory rates (state II) and a low respiratory capacity in state III ADP stimulation and in FCCP-stimulated maximal respiration in the ANG II group (Fig. 7B) . Consistent with the lowered mitochondrial respiratory capacity, the mitochondrial cytochrome c level was reduced in the ANG II group (Fig. 7 , C and D). One consequence of defects in the mitochondrial respiratory chain is the inability to maintain ionic gradients across the mitochondrial inner membrane, leading to membrane depolarization. PINK1 is selectively stabilized on depolarized mitochondria to activate Parkin, which promotes PINK1/Parkin-dependent mitophagy. Consistently, an increase in PINK1 expression was detected in whole tissue lysates as early as 1 day (detected in the presence of colchicine; Fig. 2 , G White arrowheads indicate abnormal mitochondria, characterized by swollen shape, disorganized cristae (indicated by black arrow), and matrix dissolution (indicated by asterisk). C: ratio of abnormal mitochondria to total mitochondrial number in EDL muscle of PF and ANG II-infused mice at 1, 4, and 7 days. n ϭ 5 or 6/group. D: frequency distribution of mitochondrial area in EDL muscle of PF and ANG II mice at 7 days of ANG II infusion. n ϭ 6/group. E: average mitochondrial area from EDL muscle in PF and ANG II groups at 7 days of ANG II infusion. n ϭ 6 mice/group. F: number of cristae normalized by average mitochondrial surface area in PF and ANG II groups after 7 days of infusion. n ϭ 6/group. G: average of mitochondrial crista length in PF and ANG II groups after 7 days of infusion. n ϭ 6/group. Ten-to twelve-week-old male FVB mice were used for all experiments. All data are means Ϯ SD. n ϭ 3 for 12 h, 5 for 1 day, 6 for 4 and 7 days. *P Ͻ 0.05, **P Ͻ 0.005, ***P Ͻ 0.0005. Student's t-test for E-G.
and J) and remained at these levels at 4 and 7 days after ANG II infusion (Fig. 7, E and F) . Increased PINK1 accumulation was also observed in isolated mitochondria from the ANG II group (Fig. 7, G and H) . In addition, ANG II reduced protein levels of PGC-1␣ (Fig. 7, I and J) and Mitofusin2 (Mfn2) at 4 and 7 days, OPA1 at 7 days, and Fis1 at 4 and 7 days (Fig. 7,  I and K-M) .
DISCUSSION
Our initial hypothesis that ANG II would increase autophagy in skeletal muscle was proven to be incorrect. We found that ANG II infusion blunted LC3B conversion, increased p62 and PINK1 protein expression ( Figs. 2 and 7) , decreased autophagic vacuole formation, and promoted accumulation of abnormal mitochondria in skeletal muscle ( Figs. 3 and 6 ). Moreover, ANG II infusion diminished oxidative phosphorylation (OXPHOS) of mitochondria ( Fig. 7) . Together, these data strongly suggest that ANG II impairs autophagy (9, 37, 38) and skeletal muscle energy metabolism.
In our ANG II infusion model, dynamic changes in autophagy-regulating molecules were observed throughout the experimental period, which underscores the importance of time course analyses to assess changes in autophagy in vivo. Importantly, our data showed that PINK1 and p62 were increased in the ANG IIϩcolchicine group after 1 day (Fig. 2, G, I, and  J) . Increased PINK1 indicates that ANG II-induced mitochondrial depolarization (39, 46, 60) occurs as early as 1 day and suggests that the slight (but not statistically significant) increase in LC3B conversion at this time may be due to a compensatory mechanism to degrade depolarized mitochondria via mitophagy. However, autophagy was not sufficiently activated, as indicated by reduced LC3B-I to -II conversion and by accumulation of p62 at later time points. TEM analyses revealed a reduction in the number of autophagic vacuoles in the ANG II group, further supporting the observation that ANG II suppresses autophagic activity and mitophagy, ultimately impairing skeletal muscle energy homeostasis. In fact, persistent reduction in autophagic activity compromising skeletal muscle has been reported in several genetic muscle disorders such as collagen VI muscular dystrophy, Pompe disease, and Danon disease (23, 34, 40, 47, 57) . In these pathophysiological conditions, blunted autophagic flux suppresses degradation of unwanted intracellular contents, leading to myopathy. Similar to mitochondrial abnormalities reported in these conditions, the ANG II infusion model strongly suggests that a reduction in autophagic flux and cargo degradation may be the underlying cause of skeletal muscle wasting in this model.
The reduction in autophagosome formation in the ANG II group is most likely due to inhibition of AMPK and activation of mTORC1 signaling, resulting in inhibition of ULK1, a serine-threonine kinase involved in autophagy during stress (16, 30) . It has been shown that AMPK and mTORC1 differentially regulate initial stages of the autophagosome formation: AMPK activation initiates autophagy, whereas activation of mTORC1 decreases autophagy (9, 16) . AMPK and mTORC1 coordinately regulate ULK1 activity via different phosphorylation sites: AMPK may activate ULK1 by phosphorylating at serine residues 317, 555, 467, and 777, whereas mTORC1 may downregulate ULK1 via phosphorylation of Ser757 (9, 16).
Here we report that ANG II increased Ser757 phosphorylation of ULK1 (mTORC1 site) but decreased Ser317 phosphorylation (AMPK site), both of which would result in reduced ULK1 activity. Interestingly, we did not observe changes in ULK1 phosphorylation at Ser555 (also an AMPK site). It has been shown that ULK1 site phosphorylation by AMPK depends on the primary stimuli: Ser317 and Ser777 phosphorylation of ULK1 is required for its activation and autophagy upon glucose withdrawal, whereas Ser555 phosphorylation is critical during amino acid starvation (30, 44, 49, 51) , although the precise mechanism of these AMPK-mediated differential ULK1 phosphorylation sites is unclear and warrants further investigations to help us better understand the exact skeletal muscle metabolic changes caused by ANG II.
AMPK has been shown to negatively regulate mTORC1 activity by phosphorylation of Tuberous Sclerosis Complex Subunit 2 (TSC2) and Regulatory Associated Protein of MTOR Complex 1 (Raptor), and mTORC1-dependent ULK1 phosphorylation at Ser757 is shown to disrupt ULK1-AMPK interaction, thus forming a negative feedback loop (30, 52) . Once the cellular energy is depleted, AMPK is activated and inhibits mTORC1 activity and ULK1 phosphorylation at Ser757. It is interesting that Ser757 phosphorylation of ULK1 preceded that of Ser317, which may indicate that ANG II-mediated alteration of the AMPK-mTORC1 axis is initiated by activation of the mTORC1 pathway. The changes in the AMPK-mTORC1 axis will likely lead to reduced ULK1 activity and VPS34 complex formation, critical steps involved in initiating the autophagosome formation (3, 51) . Among the several VPS34 complexes, the proautophagic complex that regulates autophagosome formation comprises VPS15, beclin-1, and ATG14 (3). Upon ULK1 activation, beclin-1 is phosphorylated at Ser14, leading to activation of the proautophagic beclin-1-VPS34-ATG14 complex (51) . ATG14 determines the role of VPS34 complex in the assembly of the autophagosome, and ULK1 activates ATG14 via Ser29 phosphorylation (42) . Consistent with the reduced ULK1 activity, we found that ANG II reduced phosphorylation of beclin-1 at Ser14 and ATG14 at Ser29 (Fig. 5 ). Together, these data indicate that ANG II impairs the initial signaling involved in autophagy activation. Moreover, they suggest that reduced activity of the beclin-1-VPS34-ATG14 complex may be the critical underlying mechanism of ANG II-mediated suppression of autophagosome formation and autophagic activity.
Upon mitochondrial damage (e.g., mitochondrial depolarization), PINK1 is selectively accumulated/stabilized on the outer mitochondrial membrane and recruits Parkin, which induces ubiquitination of mitochondrial proteins (33, 39) . Tagged depolarized mitochondria can then be recognized by autophagosome receptors such as p62 for later degradation by the autolysosome (62) . Our data show that ANG II caused a sustained increase in mitochondrial PINK1 expression (Fig.  2, G and J, and Fig. 7, E-H) , which strongly suggests that the proper clearance of unwanted mitochondria is reduced within 24 h of ANG II infusion and, importantly, persists throughout the experimental period. This is likely the cause for the accumulation of abnormal mitochondria (swollen shape with reduced number and shorter length of cristae as well as the presence of matrix dissolution) seen in TEM micrographs ( Figs. 3 and 6 ). It is of note that whereas a larger size could indicate healthier mitochondria, this is not likely the case in the ANG II infusion model because we found reduced expression of mitochondrial dynamics markers (Mfn2, OPA1, and Fis1), which suggests impaired mitochondrial quality control (50) . These mitochondrial morphological abnormalities in the ANG II group are similar to those reported in skeletal muscles with myopathy such as in Ullrich congenital muscular dystrophy and extraocular muscle under chronic progressive external ophthalmoplegia (1, 8) as well as in conditions of high-fat diet (32) . We also observed an association between abnormal mitochondria and reduced function, as ANG II significantly reduced the mitochondrial aerobic respiratory capacity (Fig. 7) . It is interesting to note that we observed lowered basal mitochondrial respiration only in complex II (succinate dehydrogenase). It has been reported that a mutation in the Sdha gene, which is a subunit of complex II, may lead to development of skeletal muscle weakness and myopathy in patients (25, 27) , which are features of reduced autophagic activity (55) . The lowered mitochondrial respiration was also associated with reduced expression of cytochrome c, which participates in OXPHOS by accepting and transferring electrons from complex III to complex IV (43), along with reduced AMPK activity and PGC-1␣ expression ( Figs. 5 and 7) . AMPK/PGC-1␣ signaling is critical in sensing the energy status and links it to induction of transcriptional programs that control energy expenditure. AMPK/PGC-1␣ has also been shown to generate new mitochondria and improve muscle oxidative metabolism in healthy skeletal muscles (20, 26, 28, 35, 56) . Furthermore, PGC-1␣ reduces oxidative stress by promoting the expression of antioxidant enzymes. Therefore, a reduced AMPK-PGC-1␣ axis might be the underlying cause of ANG II-mediated mitochondrial dysfunction. Importantly, we have previously shown that ANG II infusion reduces skeletal muscle ATP content, which likely contributes to skeletal muscle wasting (61) .The present study strongly suggests that ATP depletion is due to decreased mitochondrial OXPHOS caused by increased mitochondrial damage and reduced clearance of damaged/dysfunctional mitochondria.
In summary, our data provide novel insights into the mechanism of ANG II-mediated skeletal muscle autophagy and energy metabolism. Taken together with our previous studies, ANG II activates UPS (7, 64) and decreases autophagy in skeletal muscle. It is interesting to note that increased UPS and reduced autophagy are associated with sarcopenia in aging, in which the renin-angiotensin system is known to be activated (11) . These observations suggest that increased ANG II is the underlying cause not only of cachexia (45) but also of agingassociated sarcopenia. Importantly, our data indicate that the ULK1-beclin-1-VPS34 axis plays a central role in ANG IImediated suppression of skeletal muscle autophagy and defect in mitochondrial metabolism (Fig. 8 ). Further studies are war- ranted to target the ULK1-beclin-1 axis to develop a therapeutic approach to reverse skeletal muscle wasting in chronic diseases and aging that is associated with high levels of ANG II. 
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